Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation?

Area of Science:

• Tuberculosis research
• Drug development
• Preclinical modeling

Background:

• Fluoroquinolone-containing regimens failed to shorten tuberculosis treatment duration in recent phase 3 trials.
• This outcome has cast doubt on the predictive accuracy of preclinical tuberculosis models, particularly murine models.
• Concerns exist regarding the current paradigm for developing new tuberculosis treatment regimens.

Purpose of the Study:

• To re-evaluate the reliability of preclinical tuberculosis models.
• To assess the consistency of phase 3 trial results with earlier preclinical and clinical data.
• To propose improvements for future tuberculosis regimen development programs.

Main Methods:

• Re-examination of data from murine models of tuberculosis.
• Analysis of data from early-stage clinical trials.
• Comparison of phase 3 trial outcomes with preceding study results.

Main Results:

• Phase 3 trial results for fluoroquinolone-containing regimens were consistent with data from preceding preclinical and early-stage clinical studies.
• The failure in phase 3 trials was not an anomaly but reflected earlier trends.
• Preclinical models, while imperfect, showed alignment with clinical outcomes.

Conclusions:

• The current paradigm for tuberculosis regimen development requires re-evaluation.
• Suggestions are provided for a more integrated preclinical and clinical development program.
• Implementation of quantitative pharmacokinetic and pharmacodynamic models is recommended for better prediction of treatment efficacy.